Stefania Gonfloni

Nome e Cognome                   Stefania Gonfloni

Luogo e data di Nascita          Roma, 01.12.1967

Nazionalità                             Italiana

e-mail                                    stefania.gonfloni@uniroma2.it

Formazione

1995                                        PhD in Biofisica presso la Scuola Internazionale di Studi Superiori Avanzati (SISSA/ISAS), Trieste, Italia                       

1993                                        Magister Philosophiae in Biofisica presso la Scuola Internazionale di Studi Superiori Avanzati (SISSA/ISAS), Trieste, Italia

1991                                        Laurea in Scienze Biologiche, Università degli studi di Roma “Tor Vergata”. Voto:110/110 e lode

Incarichi di Ricerca/Attività Professionali

Dicembre 2022-oggi               Professore Associato, settore scientifico disciplinare BIO/18-Genetica

Marzo 2021-oggi                    Coordinatore Master I livello in Gestione della Sperimentazione Clinica in Ematologia ed Oncologia, Scuola                                                                                                  IaD - Università degli Studi di Roma “Tor Vergata”

Novembre 1999 –2022           Ricercatore confermato, settore scientifico disciplinare BIO/18-Genetica

12/1999 - 04/2001                  Borsa di studio di post-dottorato presso “The Rockefeller University” New York, USA, - Prof. John Kuriyan.

02/1996 -11/1999                   Borsa di studio di post-dottorato presso l’European Molecular Biology (EMBL) – Heidelberg (Germany), -                                                                                                      Prof. Giulio Superti-Furga

10/1995 - 01/1996                 Borsista presso Medical Research Council (MRC) Cambridge, UK, - Supervisor Prof. Antonino Cattaneo.

10/1991 - 12/1995                 Studente di dottorato presso la Scuola Internazionale Superiore Studi Avanzati, (SISSA), Settore di Biofisica.                                                                                                  Tesi: “Recombinant Antibodies as Structural Probes for Neurotrophins”, sotto la guida del Prof. Antonino Cattaneo.

04/10/1993                            Magister Philosophiae in Biofisica. Tesi: “The neuroantibody Approach: Cloning and Expression of Anti NT-3                                                                                                Hybridoma Variable Regions for in vivo and in vitro Studies” sotto la guida del Prof. Antonino Cattaneo.

03/1989 – 05/1991                Laureando presso il Dipartimento di Biologia, Università degli Studi di Roma Tor Vergata, Tesi: “Influenza                                                                                                      del contesto strutturale sulla conformazione e proprietà di un oligopeptide derivato da IL1b” sotto la guida del Prof. Gianni Cesareni.

Partecipazione scientifica a progetti di ricerca internazionali e nazionali

-Prin (2001-2003) 12 mesi, Ricercatore “La specificità di riconoscimento di domini che legano peptidi fosforilati”.

-Prin (2003-2005) 13 mesi, Ricercatore “Specificità di riconoscimento ed interazioni dei domini proteici FHA e 14-3-3”.

-EU FP7 Affinomics (2008-2013) (400.628,00) 60 mesi, Ricercatore “Protein Binders for Characterisation of Human Proteome Function: Generation, Validation, Application”.

-Grant Mission Substainability, (2018) (18.000,00) 12 mesi, Ricercatore, Università di Roma Tor Vergata, Ricercatore “Study of the Role of ATM and c-Abl in Fronto Temporal Dementia”

-Progetto Lazio Innova 2021, Ricercatore “Sviluppo di un kit per la prevenzione dell’osteoporosi basato su rischio genetico e stile di vita” Progetto N. A0375-2020-36631

-Progetto (2023-2026) Ricercatore, “Immunoterapia: cura e prevenzione di malattie infettive e tumorali (Immuno-HUB) finanziato dal Ministero della Salute –Traiettoria 4, “Biotecnologie, Bioinformatica e Sviluppo Farmaceutico” Azione 4.1 “Creazione di Hub delle Scienze della Vita” del Piano di Sviluppo e Coesione Salute- FSC 2014-2020 (Codice T4-CN-02)

Finanziamenti ottenuti come Responsabile Scientifico

-AIRC (2001-2004) (75.000,00) 36 mesi “Structural studies of the molecular interaction between p53 mutants and different isoforms of p73”.

-Télévie (2011-2013) (co-Principal Investigator Prof. Marc Diederich (LBMCC) Luxembourg) “Abl inhibitors to protect germ cells following genotoxic stress” (80.000,00) 24 mesi

-AIRC (2011-2014) (240.000,00) 36 mesi, “Strategies for preserving fertility under cancer treatment”

-Individual Grant MIUR 2017 (3.000,00)

-Grant di Ateneo, Università degli Studi di Roma “Tor Vergata” - 2021 “3D cell culture: studying Chemotherapy-Induced Pathways IN human Granulosa cells” 12 mesi, (13.110,00)

Partecipazione a comitati editoriali di riviste

Topic Editor, International Journal of Molecular Sciences (MDPI) da 2020-presente

https://www.mdpi.com/journal/ijms/special_issues/DNA_Damage_Response_Update

https://www.mdpi.com/journal/ijms/special_issues/moleculargerm_cells

Borse di studio internazionali

-Borsa di studio Post-dottorato Postdoctoral -Human Capital and Mobility Programme (n. ERBCHBGCT940532) EMBL-Heidelberg, Germania dal 02/1996 al 02/1998.

-Borsa di studio della Fondazione “Blanceflor Boncompagni-Ludovisi” utilizzata presso l’European Molecular Biology Laboratory, EMBL-Heidelberg, Germania dal 03/1998 al 11/1999.

-Borsa di studio post-dottorato “Howard Hughes Medical Institute” utilizzata presso il Lab. of Molecular Biophysics HHMI, The Rockefeller University, NY USA dal 12/1999-04/2001.

-Borsa di studio in qualità di visiting researcher utilizzata presso l’University of California, Berkeley USA dal 02/2003 al 04/2003.

Partecipazione a enti o istituti di ricerca, esteri e internazionali, di alta qualificazione

Visiting researcher - Laboratorie de Biologie Moléculaire et Cellulaire du Cancer (LBMCC) diretto dal Prof. Marc Diederich, Lussemburgo, dal 09/2008 –2018

Altra attività scientifica

-Socio ESHRE (European Society for Human reproduction and Embryology); -Socio SRF (Society for Reproduction and Fertility)

Conseguimento di premi e riconoscimenti per l'attività scientifica

Premio di Laurea assegnato dal Consorzio Roma Ricerche per la migliore tesi di laurea svolta nel campo delle Biotecnologie, 01-06-1991

-Articolo di commento “News and Views” in Nature Structural Biology 08-08-1999; -Articolo di commento “News and Views” In Nature Medicine 01-10-2009; -Articolo di commento in Signaling Gateway 01-10-2009; -Articolo di commento in Editors’ choice in Science Signaling 20-10-2009; -Articolo di commento nella rivista “Le Scienze”01-11-2009.

Revisore Ad Hoc per le seguenti riviste scientifiche: Cell Death & Differentiation, Biochemical Pharmacology, The International Journal of Biochemistry & Cell Biology, Cell Death and Diseases, Journal of Cancer Prevention, Reproductive Biology and Endocrinology, Molecular Human Reproduction, Experimental Cell Research, Cancers, Scientific Reports, Cell Cycle, Oncogene, International Journal of Molecular Sciences, Cells, Science Advances da 2008-oggi

Revisore di richieste di finanziamento di progetti: 2014- “The Czech Science Foundation” - Repubblica Ceca dal 01-07-2014 al 01-10-2014; 2021- “Medical Research Council”, UKRI MRC (UK Research and Innovation), Inghilterra dal 01-07-2021 al 01-09-2021; 2024- “United States-Israel Binational Science Foundation”, Israele dal 01-02-2024- al 18-04-2024

Pubblicazioni

1.  Contributo in volume - Cesareni G, Castagnoli L, Felici F, Helmer Citterich M, Jappelli R, Tataseo P, Gonfloni S, Musacchio A (1990) Protein vector and oligopeptide libraries for the selection of clone with specific binding properties Amity, 5, p.332-339.

2. Contributo in volume - Castagnoli L, Vetriani C, Gonfloni S, Felici F, Santiago Vispo N, Cesareni G (1993) Selection from a Peptide Library of the Antigenic Determinants of a Protein. Generation of Antibodies by Cell and Gene Immortalization. C. Terhorst, F. Malavasi and A. Albertini, eds. Year Immunol. Basel, Switzerland: Karger AG, 7, p.41-49.

3. Contributo in volume: Ghiara P, Villa L, Rappuoli R, Gonfloni S, Castagnoli L, Cesareni G (1993). Recombinant Protein Antigens with ‘Built in’ Adjuvancy. New Generation Vaccines p.149-154, Springer, ISBN: 978-1-4615-2948-4.

4. Beckers W, Villa L, Gonfloni S, Castagnoli L, Newton SM, Cesareni G, Ghiara P (1993)Increasing the Immunogenicity of Protein Antigens through the Genetic Insertion of VQGEESNDK Sequence of Human IL-1binto their Sequence, Journal of Immunology, 151(4), p.1757-1764.           

5. Monografia – trattato scientifico Gonfloni S* (1993) The neuroantibody approach: cloning and expression of anti NT-3 hybridoma variable regions for in vivo and in vitro studies, p. 1-53, Magister philosophiae Thesis. SISSA, Trieste

6. Contributo in volume - Bradbury A, Ruberti F, Werge T, Amati V, Di Luzio A, Gonfloni S, Hoogenboom H, Piccioli P, Biocca S, Cattaneo A (1995)The cloning of hybridoma V regions for their ectopic expression in intracellular and intercellular immunisation. Antibody engineering II: a pratical approach, IRL Press, Oxford, Washington DC.

7. Monografia -  trattato scientifico Gonfloni S*(1995). Recombinant Antibodies as Structural Probes for Neurotrophins; p.1-188, PhD thesis.  SISSA, Trieste.

8. Superti-Furga G, Gonfloni S (1997). A crystal milestone: the structure of regulated Src, BioEssays, 19(6), p.447-450.

9. Iannolo G, Minenkova O, Gonfloni S, Castagnoli L Cesareni G (1997) Construction, Exploitation and Evolution of a New Peptide Library Displayed at High Density by Fusion to the Major Coat Protein of Filamentous Phage. Biological Chemistry, 378 (6), p.517-521.

10. Williams JC, Weijland A, Gonfloni S, Thompson A, Courtneidge SA, Superti-Furga G, Wierenga RK (1997) The 2.35Å Crystal Structure of the Inactivated Form of Chicken Src: A Dynamic Molecule with Multiple Regulatory Interactions.Journal of Molecular Biology, 274, p.757-775.

11. Gonfloni S, Williams JC, Hattula K, Weijland A, Courtneidge SA, Wierenga RK, Superti-Furga G (1997) The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. EMBO Journal, 16(24), p.7261-7271.

12. Superti-Furga G, Barilà D, Dorey K, Gonfloni S (1998). Regulation of the Src and Abl protein tyrosine kinases. FASEB Journal, 8, A1324 Suppl. S.

13. Molnar M, Tongiorgi E, Avignone E, Gonfloni S, Ruberti F, Domenici L, Cattaneo A (1998) The effects of Anti-NGF Monoclonal Antibody on Developing Basal Forebrain Neurons are transient and reversible. EuropeanJournal of Neuroscience, 10, p.3127-3140.

14. Gonfloni S, Frischknecht F, Way M, Superti-Furga G (1999) Leucine 255 of Src couples intramolecular interactions to inhibition of catalysisNature Structural Biology 6 (8), p.760-764.

15. Frischknecht F, Moreau V, Rottger S, Gonfloni S, Reckmann I, Miki H, Superti-Furga G, Way M (1999) Actin based motility of vaccinia virus mimics receptor tyrosine kinase signallingNature, 401 (6756), p.926-929.

16. Barilà D, Mangano R, Gonfloni S, Kretzschmar J, Moro M, Bohmann D, Superti-Furga G (2000) A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNKEMBO Journal 19 (2), p.273-281.

17. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, Rossi G, Berardi N, Cattaneo A (2000) Phenotypic knockout of nerve growh factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons.Journal of Neuroscience 20 (7), p.2589-2601.

18. Gonfloni S, Weijland A, Kretzschmar J, Superti-Furga G (2000) Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nature Structural Biology, 7 (4), p.281-286.

19. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J (2001) Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivatition by C-terminal tyrosine phosphorylation.Cell 6; 105 (1), p.115-126.

20. Giglione C, Gonfloni S, Parmeggiani A (2001) Differential Actions of p60c-Src and Lck Kinases on the Ras regulators p120-GAP and GDP/GTP exchange factor CDC25Mm.European Journal of Biochemistry, 268(11), p.3275-3283.

21. Castagnoli L, Costantini A, Dall'Armi C, Gonfloni S, Montecchi-Palazzi L, Panni S, Paoluzi S, Santonico E, Cesareni G (2004)Selectivity and promiscuity in the interaction network mediated by protein recognition modules. FEBs Letters 567, p.74-79.

22. Candi E, Cipollone R, Rivetti di Val Cervo P, Gonfloni S, Melino G and Knight R (2008) p63 in epithelial development. Cellular and Molecular Life Sciences, 65 (20), p.3126-3133.

23. Covaceuszach S, Cassetta A, Konarev PV, Gonfloni S, Rudolph R, Svergun DI, Lamba D, Cattaneo A (2008) Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody. Journal of Molecular Biology, 381, p.881-896.

24. Paoletti F, Covaceuszach S, Konarev PV, Gonfloni S, Malerba F, Schwarz E, Svergun DI, Cattaneo A and Lamba D (2009) Intrinsic Structural Disorder of Mouse proNGF. Proteins: Structure, Function, and Bioinformatics, 75, p.990-1009.

25. Gonfloni S*, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, Mattei M, Candi E, De Felici M, Melino G, Cesareni G (2009) Inhibition of the c-Abl –TAp63 pathway protects mouse oocytes from chemotherapy-induced death Nature Medicine, 15, p.1179-1185.

26. Gonfloni S*(2010)Modulating c-Abl nuclear activity as a strategy to preserve female fertilityCell Cycle, 9 (2), p.217-218.

27. Gonfloni S*(2010)DNA damage stress response in germ cells: role of c-Abl and clinical implications. Oncogene, 29 (47), p.6193-6202.

28. Maiani E, Diederich M, Gonfloni S*(2011) DNA damage response: the emerging role of c-Abl as a regolatory switch?Biochemical Pharmacology, 82 (10), p.1269-1276.

29. Gonfloni S*, Maiani E, Di Bartolomeo C, Diederich M, Cesareni G (2012) Oxidative stress, DNA damage and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases?InternationalJournal of Cell Biology, 1:683097.

30. Maiani E, Di Bartolomeo C, Klinger FG, Cannata SM, Bernardini S, S Chateauvieux S, Mack F, Mattei M, De Felici M, Diederich M, Cesareni G, Gonfloni S*(2012) in Reply to: Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinibNature Medicine, 8, p.1172-1174.

31. Gonfloni S*(2013) Targeting DNA damage response: Threshold, chromatin landscape and beyond. Pharmacology and Therapeutics, 138(1), p.46-52.

32. Ciccone S, Maiani E, Bellusci G, Diederich M, Gonfloni S*(2013)Parkinson’s Disease: a complex interplay of mitochondrial DNA alterations and oxidative stressInternational Journal of Molecular Sciences, 14 (2), p.2388-2409.

33. Gonfloni S*, Iannizzotto V, Maiani E, Bellusci G, Ciccone S, Diederich M (2014) P53 and Sirt1: Routes of metabolism and genome stability Biochemical Pharmacology, 92(1), p.149-156.

34. Gonfloni S*(2014) Defying c-Abl signaling circuits through small allosteric compoundsFrontiers in Genetics, 5:392.

35. Gonfloni S*, Caputo V, Iannizzotto V (2015) P63 in health and cancerInternational Journal of Developmental Biology, 59(1-3), p.87-93.

36. Bellusci G, Mattiello L, Iannizzotto V, Ciccone S, Maiani E, Villani V, Diederich M, Gonfloni S* (2019) Kinase-independent inhibition of cyclophosphamide-induced pathways protects the ovarian reserve and prolongs fertility Cell Death Disease, 10 (10), p.1-14.

37. Mattiello L, Pucci G, Marchetti F, Diederich M, Gonfloni S* (2021) Asciminib Mitigates DNA damage stress Signaling Induced by Cyclophosphamide in the OvaryInternational Journal of Molecular Sciences, 22(3):1395.

38. Gonfloni S*, Jodice C, Gustavino B, Valentini E (2022) DNA Damage Stress Response and Follicle Activation: Signaling routes of Mammalian Ovarian reserve International Journal of Molecular Sciences, 23(22):14379.

39. Dhori X.,Gioiosa S*.and Gonfloni S* (2024)An integrated analysis of multiple datasets reveals novel gene signatures in human granulosa cells Scientific Data, NPG Nature Research, in revision.

*=corresponding author